What is Foresee Genomics?
Foresee Genomics operates at the intersection of biotechnology and precision medicine, focusing on the development of advanced testing kits designed to identify multiple cancer genomic markers. By prioritizing simplicity, accuracy, and efficiency, the company addresses critical bottlenecks in current diagnostic workflows for cancer patients. Its market position is defined by a commitment to high-throughput genomic analysis, enabling clinicians to make data-informed decisions with greater speed and reliability. As the oncology sector shifts toward personalized treatment protocols, Foresee Genomics provides the essential infrastructure required to map complex genetic profiles effectively.
How much funding has Foresee Genomics raised?
Foresee Genomics has raised a total of $1.3M across 1 funding round:
Debt
$1.3M
Debt (2025): $1.3M with participation from GoodPaper Ventures
Key Investors in Foresee Genomics
GoodPaper Ventures
GoodPaper Ventures is a venture capital firm that invests in founders with innovative ideas across various industries and regions. The firm provides strategic guidance and connects founders with key industry players to enhance their chances of success.
What's next for Foresee Genomics?
With this major strategic investment, Foresee Genomics is expected to transition into a phase of rapid commercial expansion and technological refinement. The capital will likely be deployed to enhance the sensitivity of its genomic markers and to broaden the clinical utility of its testing kits across diverse oncology departments. Furthermore, the firm is positioned to strengthen its regulatory standing and expand its footprint in the global diagnostics market. By leveraging this financial backing, Foresee Genomics aims to solidify its role as a foundational player in the future of cancer diagnostics, potentially setting new benchmarks for diagnostic accuracy and operational efficiency in the clinical setting.
See full Foresee Genomics company page
